174721-08-5Relevant articles and documents
Microbial transformation of 20(S)-protopanaxatriol-type saponins by Absidia coerulea
Chen, Guangtong,Yang, Min,Lu, Zhiqiang,Zhang, Jinqiang,Huang, Huilian,Liang, Yan,Guan, Shuhong,Song, Yan,Wu, Lijun,Guo, De-An
, p. 1203 - 1206 (2007)
Three 20(S)-protopanaxatriol-type saponins, ginsenoside-Rg1 (1), notoginsenoside-R1 (2), and ginsenoside-Re (3), were transformed by the fungus Absidia coerulea (AS 3.3389). Compound 1 was converted into five metabolites, ginsenoside-Rh4 (4), 3β,2β,25- trihydroxydammar-(E)-20(22)-ene-6-O-β-D-glucopyranoside (5), 20(S)-ginsenoside-Rh1 (6), 20(R)-ginsenoside-Rh1 (7), and a mixture of 25-hydroxy-20(S)-ginsenoside-Rh1 and its C-20(R) epimer (8). Compound 2 was converted into 10 metabolites, 20(S)-notoginsenoside-R 2 (9), 20(R)-notoginsenoside-R2 (10), 3β,12β,25- trihydroxydammar-(E)-20(22)-ene-6-O-β-D-xylopyranosyl-(1→2) -β-D-glucopyranoside (11), 3β,12β-dihydroxydammar-(E)-20(22),24- diene-6-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside (12), 3β,12β,20,25-tetrahydroxydammaran-6-O-β-D-xylopyranosyl- (1→2)-β-D-glucopyranoside (13), and compounds 4-8. Compound 3 was metabolized to 20(S)-ginsenoside-Rg2 (14), 20(R)-ginsenoside-Rg 2 (15), 3β,12β,25-trihydroxydammar-(E)-20(22)-ene-6-O- α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranoside (16), 3β,12β-dihydroxydammar-(E)-20(22),24-diene-6-O-α-L- rhamnopyranosyl-(1→2)-β-D-glucopyranoside (17), 3β,12β,20, 25-tetrahydroxydammaran-6-O-α-L-rhamnopyranosyl-(1→2) -β-D-glucopyranoside (18), and compounds 4-8. The structures of five new metabolites, 10-13 and 16, were established by spectroscopic methods.
Manufacturing method for mass-production of ginsenoside Rh4
-
Paragraph 0066-0067, (2017/04/29)
The present invention relates to a method for mass-producing Ginsenoside-Re, and more specifically, to a method for mass-producing Ginsenoside-Re in which organic acid is mixed with Ginsenoside-Re and the mixture is treated under high temperature and high pressure, to produce Ginsenoside-Rh4. Ginsenoside-Rh4 exists in a small amount, only in red ginseng and black ginseng but not in white ginseng, and the conventional means to extract Ginsenoside-Rh4 by treating a ginseng extract and a red ginseng extract is not only ineffective in isolating and purifying Ginsenoside-Rh4, due to the presence of various other ginsenosides having similar chemical structures and molecular weights, but also results in a very low yield of isolated and purified Ginsenoside-Rh4, because Ginsenoside-Rh4 is present only in a miniscule amount in such extracts. On the other hand, the present invention produces Ginsenoside-Rh4 only by using Ginsenoside-Re capable of being easily isolated from ginseng leaves. Therefore, the isolation and purification of Ginsenoside-Rh4 is easier than when using extracts, and the mass-production of the same is markedly easy. Also, since Ginsenoside-Rh4 isolated and purified by the conventional means is costly, the method for mass-producing Ginsenoside-Rh4 according to the present invention, which enables Ginsenoside-Rh4 to be produced inexpensively, can generate higher value-added.COPYRIGHT KIPO 2016
